The present invention relates to fused pyrrolidino-cyclopropane derivatives according to Formulae (I) to (II), as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-β-HSD-1 ) and the use of such compounds for the treatment and/or prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis/ cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
